We Cure Viral Diseases with Non-Pathogenic Viruses!
Our mission is to develop all-oral cure for hepatitis patients suffering from decompensated disease resistant to all currently available therapies. To achieve this goal, we exploit clinically tested viral competition between pathogenic viruses (HBV/HCV) and an attenuated non-pathogenic double stranded RNA virus. As the world faces major threats of emerging or reemerging organisms, increased drug resistance, and intentional or unintentional spread of virulent pathogens, we leverage our superinfection technology platform for the postexposure treatment of pandemic influenza, dengue and Ebola virus infections.
HepC, Inc. is a privately-held biotechnology firm based in Budapest, Hungary and Rockville, Maryland. The Company was founded as an Ltd in 2005 and converted to incorporation in 2014. Shortly after its foundation, HepC has established a strategic alliance with VectorLogics, Inc. (VLI) in the USA. Based upon the IBDV technology and science VLI has raised almost $400 thousand from grants and invested its own scientific know-how to progress the project. Since VLIís merger with DNAtrix, Inc. in 2012, the VLI IBDV vector portfolio was transferred to ImiGene, Inc. of Delaware, USA. HepC has acquired the IBDV vector portfolio and know-how under a new licensing agreement with ImiGene for equity stake in HepC, Inc. HepCís USA business office is now located in Rockville, Maryland.
HepC Inc is a biotechnology company focused on the development and commercialization of antiviral biologic products. Its lead clinical program is targeting advanced chronic hepatitis B and C infections (HBV and HCV) with unmet needs, particularly for decompensated hepatitis and for the adjuvant therapy of HBV/HCV positive hepatocellular carcinoma (HCC) with fragile liver function.
Despite the spectacular success of antiviral therapy in preventing cirrhosis complications in HBV and HCV hepatitis, decompensation is still a major unresolved problem with poor outcome. Innovative new treatments are required for this patient population. The infectious bursal disease virus (IBDV) superinfection therapy (SIT) is such a treatment. IBDV is a non-pathogenic double stranded RNA (dsRNA) virus, a master activator of antiviral gene responses. HepCís goal is to develop its R903/78 antiviral biological drug candidate, which is produced from an attenuated vaccine strain by reverse genetics for the interferon-free, oral superinfection treatment of decompensated patients, who have the least time available and the most to lose.
The Company is also actively evaluating other viral diseases with unmet needs such as influenza (Flu), West Nile virus (WNV), dengue virus (DENV) and Ebola virus (EDV) which our SIT technology could target.